[S02DA03, antipyrine, The metabolism of Lacosamide can be decreased when combined with Antipyrine.]
[G03XB02, ulipristal, The metabolism of Ulipristal can be increased when combined with Lacosamide.]
[L04AA27, fingolimod, Lacosamide may increase the bradycardic activities of Fingolimod.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Lacosamide.]
[J01EC02, sulfadiazine, The metabolism of Lacosamide can be decreased when combined with Sulfadiazine.]
[S01AB01, sulfamethizole, The metabolism of Lacosamide can be decreased when combined with Sulfamethizole.]
[J01EC01, sulfamethoxazole, The metabolism of Lacosamide can be decreased when combined with Sulfamethoxazole.]
[J01EC03, sulfamoxole, The metabolism of Lacosamide can be decreased when combined with Sulfamoxole.]
[J01EB04, sulfapyridine, The metabolism of Lacosamide can be decreased when combined with Sulfapyridine.]
[M04AB02, sulfinpyrazone, The metabolism of Lacosamide can be decreased when combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, The metabolism of Lacosamide can be decreased when combined with Sulfisoxazole.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Sulpiride is combined with Lacosamide.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Lacosamide is combined with Sulthiame.]
[A10BB04, glibornuride, The metabolism of Glibornuride can be decreased when combined with Lacosamide.]
[L01BB02, mercaptopurine, Lacosamide may increase the excretion rate of Mercaptopurine which could result in a lower serum level and potentially a reduction in efficacy.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Lacosamide.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Lacosamide.]
[L01CB02, teniposide, The metabolism of Teniposide can be decreased when combined with Lacosamide.]
[G03BA03, testosterone, The metabolism of Lacosamide can be increased when combined with Testosterone.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Lacosamide is combined with Tetracaine.]
[S03AA02, tetracycline, The metabolism of Lacosamide can be decreased when combined with Tetracycline.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Lacosamide is combined with Lurasidone.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Lacosamide.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Lacosamide.]
[L04AX02, thalidomide, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, Lacosamide may increase the excretion rate of Theobromine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Lacosamide.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Lacosamide.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be decreased when combined with Lacosamide.]
[N05CA19, thiopental, The risk or severity of adverse effects can be increased when Thiopental is combined with Lacosamide.]
[N05AB08, thioproperazine, The risk or severity of adverse effects can be increased when Thioproperazine is combined with Lacosamide.]
[N05AC02, thioridazine, The risk or severity of adverse effects can be increased when Thioridazine is combined with Lacosamide.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Thiothixene is combined with Lacosamide.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Lacosamide is combined with Tiapride.]
[B01AC05, ticlopidine, The metabolism of Lacosamide can be decreased when combined with Ticlopidine.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Lacosamide is combined with Tilidine.]
[S01ED01, timolol, The metabolism of Lacosamide can be decreased when combined with Timolol.]
[A10BB05, tolazamide, The metabolism of Lacosamide can be decreased when combined with Tolazamide.]
[V04CA01, tolbutamide, The metabolism of Lacosamide can be decreased when combined with Tolbutamide.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Lacosamide is combined with Tolperisone.]
[N02AX02, tramadol, The risk or severity of CNS depression can be increased when Lacosamide is combined with Tramadol.]
[N06AF04, tranylcypromine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lacosamide.]
[N06AX05, trazodone, The risk or severity of adverse effects can be increased when Lacosamide is combined with Trazodone.]
[L01XF01, tretinoin, The metabolism of Lacosamide can be decreased when combined with Tretinoin.]
[S01BA05, triamcinolone, The metabolism of Lacosamide can be increased when combined with Triamcinolone.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Triazolam is combined with Lacosamide.]
[A03AB12, mepenzolate, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[N05AB06, trifluoperazine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Lacosamide.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Lacosamide is combined with Trifluperidol.]
[N05AA05, triflupromazine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.]
[N04AA01, trihexyphenidyl, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[R03BA07, mometasone, The metabolism of Lacosamide can be increased when combined with Mometasone.]
[A03AA05, trimebutine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Alimemazine is combined with Lacosamide.]
[N03AC02, trimethadione, The risk or severity of adverse effects can be increased when Trimethadione is combined with Lacosamide.]
[J01EA01, trimethoprim, The metabolism of Lacosamide can be decreased when combined with Trimethoprim.]
[N06AA06, trimipramine, The risk or severity of adverse effects can be increased when Trimipramine is combined with Lacosamide.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Triprolidine is combined with Lacosamide.]
[A03BB01, butylscopolamine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[J01FA08, troleandomycin, The metabolism of Lacosamide can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The risk or severity of adverse effects can be increased when Lacosamide is combined with Vilazodone.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Lacosamide.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Tubocurarine is combined with Lacosamide.]
[R03DX07, roflumilast, The metabolism of Lacosamide can be decreased when combined with Roflumilast.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be decreased when combined with Lacosamide.]
[A10BH05, linagliptin, The metabolism of Lacosamide can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Lacosamide can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Lacosamide can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The metabolism of Lacosamide can be decreased when combined with Rilpivirine.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Ezogabine is combined with Lacosamide.]
[B01AC24, ticagrelor, The metabolism of Lacosamide can be decreased when combined with Ticagrelor.]
[C08DA01, verapamil, The metabolism of Lacosamide can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Lacosamide can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Vinblastine can be decreased when combined with Lacosamide.]
[L01CA02, vincristine, The metabolism of Vincristine can be decreased when combined with Lacosamide.]
[L01CA03, vindesine, The metabolism of Vindesine can be decreased when combined with Lacosamide.]
[A11HA03, vitamin E, The metabolism of Lacosamide can be increased when combined with Vitamin E.]
[B01AA03, warfarin, The metabolism of Warfarin can be decreased when combined with Lacosamide.]
[S01AA13, fusidic acid, The metabolism of Lacosamide can be decreased when combined with Fusidic acid.]
[J05AF01, zidovudine, The metabolism of Lacosamide can be decreased when combined with Zidovudine.]
[N05AF05, zuclopenthixol, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Lacosamide.]
[J05AE02, indinavir, The metabolism of Lacosamide can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Levetiracetam is combined with Lacosamide.]
[L01EC01, vemurafenib, The metabolism of Vemurafenib can be decreased when combined with Lacosamide.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be decreased when combined with Lacosamide.]
[L01ED01, crizotinib, Crizotinib may increase the bradycardic activities of Lacosamide.]
[R03DC01, zafirlukast, The metabolism of Lacosamide can be decreased when combined with Zafirlukast.]
[A02BC04, rabeprazole, The metabolism of Lacosamide can be decreased when combined with Rabeprazole.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Lacosamide is combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Drospirenone can be increased when combined with Lacosamide.]
[N02BA01, aspirin, The metabolism of Lacosamide can be decreased when combined with Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, Ruxolitinib may increase the bradycardic activities of Lacosamide.]
[G04BD07, tolterodine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[C07AB03, atenolol, Atenolol may increase the bradycardic activities of Lacosamide.]
[J02AC03, voriconazole, The metabolism of Lacosamide can be decreased when combined with Voriconazole.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Lacosamide is combined with Atracurium.]
[S01FA01, atropine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be decreased when combined with Lacosamide.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Lacosamide.]
[R07AX02, ivacaftor, The metabolism of Lacosamide can be decreased when combined with Ivacaftor.]
[H02AB11, prednylidene, The metabolism of Lacosamide can be increased when combined with Prednylidene.]
[J01CA09, azlocillin, The therapeutic efficacy of Lacosamide can be decreased when used in combination with Azlocillin.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Lacosamide.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Lacosamide.]
[A08AA11, lorcaserin, The risk or severity of adverse effects can be increased when Lorcaserin is combined with Lacosamide.]
[V03AX03, cobicistat, The metabolism of Lacosamide can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Lacosamide can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Lacosamide can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Bosutinib can be decreased when combined with Lacosamide.]
[L01EX05, regorafenib, The metabolism of Regorafenib can be decreased when combined with Lacosamide.]
[N05CA04, barbital, The risk or severity of adverse effects can be increased when Barbital is combined with Lacosamide.]
[J05AE04, nelfinavir, The metabolism of Lacosamide can be decreased when combined with Nelfinavir.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Lacosamide.]
[N04BD02, rasagiline, The risk or severity of adverse effects can be increased when Rasagiline is combined with Lacosamide.]
[C08CA13, lercanidipine, Lercanidipine may increase the bradycardic activities of Lacosamide.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Lacosamide is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Donepezil is combined with Lacosamide.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Lacosamide.]
[L04AA29, tofacitinib, Lacosamide may increase the bradycardic activities of Tofacitinib.]
[N02CC03, zolmitriptan, The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Lacosamide.]
[R06AC06, thonzylamine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Lacosamide is combined with Diethyl ether.]
[L01EX07, cabozantinib, The metabolism of Cabozantinib can be decreased when combined with Lacosamide.]
[H01CB05, pasireotide, Lacosamide may increase the bradycardic activities of Pasireotide.]
[G04BE03, sildenafil, The metabolism of Lacosamide can be decreased when combined with Sildenafil.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Lacosamide.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Lacosamide.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be decreased when combined with Lacosamide.]
[C04AX11, bencyclane, Lacosamide may increase the bradycardic activities of Bencyclane.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Lacosamide can be increased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the bradycardic activities of Lacosamide.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be decreased when combined with Lacosamide.]
[G03XC05, ospemifene, The metabolism of Lacosamide can be decreased when combined with Ospemifene.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Lacosamide is combined with Benperidol.]
[M04AB03, benzbromarone, The metabolism of Lacosamide can be decreased when combined with Benzbromarone.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Lacosamide is combined with Benzocaine.]
[M01AH01, celecoxib, The metabolism of Lacosamide can be decreased when combined with Celecoxib.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Naratriptan is combined with Lacosamide.]
[L04AA18, everolimus, The metabolism of Everolimus can be decreased when combined with Lacosamide.]
[N04AC01, benztropine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[L01EC02, dabrafenib, The serum concentration of Lacosamide can be decreased when it is combined with Dabrafenib.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Lacosamide is combined with Benzyl alcohol.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Lacosamide is combined with Levomilnacipran.]
[C08EA02, bepridil, Bepridil may increase the bradycardic activities of Lacosamide.]
[N06AX26, vortioxetine, The risk or severity of adverse effects can be increased when Lacosamide is combined with Vortioxetine.]
[G03AC08, etonogestrel, The metabolism of Etonogestrel can be increased when combined with Lacosamide.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Lacosamide is combined with Eslicarbazepine.]
[D01AC18, luliconazole, The serum concentration of Lacosamide can be increased when it is combined with Luliconazole.]
[J05AP05, simeprevir, The metabolism of Lacosamide can be decreased when combined with Simeprevir.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Lacosamide.]
[A10BK01, dapagliflozin, The metabolism of Dapagliflozin can be decreased when combined with Lacosamide.]
[C07AB04, acebutolol, Acebutolol may increase the bradycardic activities of Lacosamide.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Lacosamide is combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Lacosamide can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Lacosamide can be increased when combined with Apremilast.]
[L02BG02, formestane, The metabolism of Lacosamide can be increased when combined with Formestane.]
[S03BA03, betamethasone, The metabolism of Lacosamide can be increased when combined with Betamethasone.]
[S01ED02, betaxolol, Betaxolol may increase the bradycardic activities of Lacosamide.]
[L04AC11, siltuximab, The metabolism of Lacosamide can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, Lacosamide may increase the bradycardic activities of Ceritinib.]
[B01AC26, vorapaxar, The metabolism of Vorapaxar can be decreased when combined with Lacosamide.]
[A03BA03, hyoscyamine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The metabolism of Acenocoumarol can be decreased when combined with Lacosamide.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be decreased when combined with Lacosamide.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Lacosamide is combined with Alfaxalone.]
[R03AC19, olodaterol, The metabolism of Olodaterol can be decreased when combined with Lacosamide.]
[D11AA01, glycopyrronium, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[N05CM19, suvorexant, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[J01XA05, oritavancin, The metabolism of Lacosamide can be increased when combined with Oritavancin.]
[N05AA04, acepromazine, The risk or severity of adverse effects can be increased when Acepromazine is combined with Lacosamide.]
[N04AA02, biperiden, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[L04AX05, pirfenidone, The metabolism of Lacosamide can be decreased when combined with Pirfenidone.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be decreased when combined with Lacosamide.]
[L01XK01, olaparib, The metabolism of Olaparib can be decreased when combined with Lacosamide.]
[B01AA01, dicumarol, The metabolism of Lacosamide can be decreased when combined with Dicoumarol.]
[N06AX11, mirtazapine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Lacosamide can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be decreased when combined with Lacosamide.]
[L01XH03, panobinostat, The metabolism of Panobinostat can be decreased when combined with Lacosamide.]
[N02BE01, acetaminophen, The metabolism of Lacosamide can be increased when combined with Acetaminophen.]
[A03AA09, difemerine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[C01EB17, ivabradine, Lacosamide may increase the bradycardic activities of Ivabradine.]
[J05AP06, asunaprevir, The metabolism of Lacosamide can be increased when combined with Asunaprevir.]
[N05AX16, brexpiprazole, The risk or severity of adverse effects can be increased when Lacosamide is combined with Brexpiprazole.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be decreased when combined with Lacosamide.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Flibanserin is combined with Lacosamide.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Cariprazine is combined with Lacosamide.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Acetazolamide is combined with Lacosamide.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Acetophenazine is combined with Lacosamide.]
[A02BC03, lansoprazole, The metabolism of Lacosamide can be decreased when combined with Lansoprazole.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Lacosamide.]
[J02AC05, isavuconazole, The metabolism of Lacosamide can be decreased when combined with Isavuconazole.]
[L01EB04, osimertinib, The metabolism of Osimertinib can be decreased when combined with Lacosamide.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Lacosamide.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be decreased when combined with Lacosamide.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be decreased when combined with Lacosamide.]
[L01ED03, alectinib, The metabolism of Alectinib can be decreased when combined with Lacosamide.]
[A10BB31, acetohexamide, The metabolism of Lacosamide can be decreased when combined with Acetohexamide.]
[M04AB05, lesinurad, The metabolism of Lacosamide can be increased when combined with Lesinurad.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Aprobarbital is combined with Lacosamide.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Brivaracetam is combined with Lacosamide.]
[L01XX52, venetoclax, The metabolism of Venetoclax can be decreased when combined with Lacosamide.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Bromazepam is combined with Lacosamide.]
[N04BC01, bromocriptine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Lacosamide.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Alverine is combined with Lacosamide.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lacosamide.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Amineptine is combined with Lacosamide.]
[C08CA01, amlodipine, Amlodipine may increase the bradycardic activities of Lacosamide.]
[N05AX17, pimavanserin, The metabolism of Lacosamide can be decreased when combined with Pimavanserin.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Aniracetam is combined with Lacosamide.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Lacosamide is combined with Bupivacaine.]
[C07AA19, bupranolol, Lacosamide may increase the bradycardic activities of Bupranolol.]
[N07BC01, buprenorphine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Buspirone is combined with Lacosamide.]
[L01AB01, busulfan, The metabolism of Busulfan can be decreased when combined with Lacosamide.]
[N06DA03, rivastigmine, Rivastigmine may increase the bradycardic activities of Lacosamide.]
[P01BE02, artemether, The metabolism of Artemether can be decreased when combined with Lacosamide.]
[M02AA03, clofezone, The metabolism of Lacosamide can be decreased when combined with Rabeprazole.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Lacosamide.]
[R06AX09, azatadine, The therapeutic efficacy of Lacosamide can be decreased when used in combination with Azatadine.]
[S01GX07, azelastine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[L01XK03, rucaparib, The metabolism of Lacosamide can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The metabolism of Lacosamide can be decreased when combined with Azithromycin.]
[L01EF02, ribociclib, The metabolism of Lacosamide can be decreased when combined with Ribociclib.]
[R03DA08, bamifylline, Lacosamide may increase the excretion rate of Bamifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BF02, pregabalin, The therapeutic efficacy of Lacosamide can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Lacosamide is combined with Beclamide.]
[N06BC01, caffeine, Lacosamide may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Lacosamide is combined with Oxybuprocaine.]
[D05AX03, calcitriol, The metabolism of Lacosamide can be increased when combined with Calcitriol.]
[J01XX08, linezolid, The therapeutic efficacy of Lacosamide can be decreased when used in combination with Linezolid.]
[J05AE09, tipranavir, The metabolism of Lacosamide can be decreased when combined with Tipranavir.]
[L04AB02, infliximab, The metabolism of Lacosamide can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Lacosamide can be decreased when combined with Midostaurin.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Lacosamide.]
[N04BD03, safinamide, The risk or severity of adverse effects can be increased when Lacosamide is combined with Safinamide.]
[L04AC14, sarilumab, The metabolism of Lacosamide can be increased when combined with Sarilumab.]
[J01MA23, delafloxacin, The metabolism of Lacosamide can be increased when combined with Delafloxacin.]
[D01AC10, bifonazole, The metabolism of Lacosamide can be decreased when combined with Bifonazole.]
[L01BC06, capecitabine, The metabolism of Lacosamide can be decreased when combined with Capecitabine.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Lacosamide.]
[L01EH02, neratinib, The metabolism of Neratinib can be decreased when combined with Lacosamide.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be decreased when combined with Lacosamide.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be decreased when combined with Lacosamide.]
[C07AB07, bisoprolol, Bisoprolol may increase the bradycardic activities of Lacosamide.]
[J05AG03, efavirenz, The metabolism of Lacosamide can be decreased when combined with Efavirenz.]
[C07AA17, bopindolol, Lacosamide may increase the bradycardic activities of Bopindolol.]
[N04AA11, bornaprine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Lacosamide is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Lacosamide is combined with Brotizolam.]
[R03BA02, budesonide, The metabolism of Lacosamide can be increased when combined with Budesonide.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be decreased when combined with Lacosamide.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Butobarbital is combined with Lacosamide.]
[J05AX18, letermovir, The metabolism of Lacosamide can be decreased when combined with Letermovir.]
[N06AA15, butriptyline, The risk or severity of adverse effects can be increased when Lacosamide is combined with Butriptyline.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Lacosamide is combined with Capsaicin.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Lacosamide is combined with Vinylbital.]
[L02BB05, apalutamide, The serum concentration of Lacosamide can be increased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The serum concentration of Lacosamide can be decreased when it is combined with Carbamazepine.]
[A03AA03, camylofine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Lacosamide.]
[C07AG02, carvedilol, Carvedilol may increase the bradycardic activities of Lacosamide.]
[B02BX09, fostamatinib, The metabolism of Lacosamide can be decreased when combined with Fostamatinib.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Lacosamide.]
[B02BX08, avatrombopag, The metabolism of Lacosamide can be increased when combined with Avatrombopag.]
[C07AB08, celiprolol, Celiprolol may increase the bradycardic activities of Lacosamide.]
[L01XX62, ivosidenib, The metabolism of Lacosamide can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The metabolism of Lacosamide can be decreased when combined with Stiripentol.]
[J05AX24, tecovirimat, The metabolism of Lacosamide can be increased when combined with Tecovirimat.]
[L01EM04, duvelisib, The metabolism of Duvelisib can be decreased when combined with Lacosamide.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Lacosamide.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Cetirizine is combined with Lacosamide.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Lacosamide is combined with Carbromal.]
[A10BB06, carbutamide, The metabolism of Carbutamide can be decreased when combined with Lacosamide.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Lacosamide is combined with Chloroprocaine.]
[R06AA06, chlorphenoxamine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, The metabolism of Lornoxicam can be decreased when combined with Lacosamide.]
[R03DA02, oxtriphylline, Lacosamide may increase the excretion rate of Oxtriphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Lacosamide.]
[R03BB08, revefenacin, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L01ED05, lorlatinib, The metabolism of Lacosamide can be increased when combined with Lorlatinib.]
[L04AA39, emapalumab, The metabolism of Lacosamide can be increased when combined with Emapalumab.]
[L01EX13, gilteritinib, The metabolism of Gilteritinib can be decreased when combined with Lacosamide.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Lacosamide is combined with Cinitapride.]
[P02BX04, triclabendazole, The metabolism of Lacosamide can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Lacosamide is combined with Esketamine.]
[L04AA42, siponimod, The metabolism of Siponimod can be decreased when combined with Lacosamide.]
[J01FA09, clarithromycin, The metabolism of Lacosamide can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of adverse effects can be increased when Lacosamide is combined with Solriamfetol.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Lacosamide is combined with Brexanolone.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Lacosamide.]
[N05BA09, clobazam, The risk or severity of adverse effects can be increased when Clobazam is combined with Lacosamide.]
[H02AB14, cloprednol, The metabolism of Lacosamide can be increased when combined with Cloprednol.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Cloxazolam is combined with Lacosamide.]
[C09CA06, candesartan, The metabolism of Lacosamide can be decreased when combined with Candesartan.]
[L04AB01, etanercept, The metabolism of Lacosamide can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The metabolism of Lacosamide can be increased when combined with Cortivazol.]
[L01EM03, alpelisib, The serum concentration of Lacosamide can be decreased when it is combined with Alpelisib.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be decreased when combined with Lacosamide.]
[J01DD01, cefotaxime, The therapeutic efficacy of Lacosamide can be decreased when used in combination with Cefotaxime.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Lacosamide is combined with Cyamemazine.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Lacosamide.]
[L01EJ02, fedratinib, The metabolism of Fedratinib can be decreased when combined with Lacosamide.]
[L01EX14, entrectinib, The metabolism of Entrectinib can be decreased when combined with Lacosamide.]
[N07XX11, pitolisant, The serum concentration of Lacosamide can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The metabolism of Lacosamide can be decreased when combined with Pretomanid.]
[J01XX12, lefamulin, The metabolism of Lefamulin can be decreased when combined with Lacosamide.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Lacosamide.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Lacosamide.]
[J01DB01, cephalexin, The metabolism of Lacosamide can be decreased when combined with Cephalexin.]
[J01DB03, cephalothin, The therapeutic efficacy of Lacosamide can be decreased when used in combination with Cefalotin.]
[J01DB09, cephradine, The metabolism of Lacosamide can be increased when combined with Cefradine.]
[H02AB13, deflazacort, The metabolism of Lacosamide can be increased when combined with Deflazacort.]
[G03DB05, demegestone, The metabolism of Demegestone can be increased when combined with Lacosamide.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be decreased when combined with Lacosamide.]
[N02CC08, lasmiditan, The risk or severity of adverse effects can be increased when Lasmiditan is combined with Lacosamide.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be decreased when combined with Lacosamide.]
[G03AC09, desogestrel, The metabolism of Desogestrel can be increased when combined with Lacosamide.]
[B06AX03, voxelotor, The metabolism of Voxelotor can be decreased when combined with Lacosamide.]
[N03AX25, cenobamate, The serum concentration of Lacosamide can be decreased when it is combined with Cenobamate.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lacosamide.]
[R06AB02, dexchlorpheniramine, The therapeutic efficacy of Lacosamide can be decreased when used in combination with Dexchlorpheniramine.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Dezocine is combined with Lacosamide.]
[L01EX18, avapritinib, The metabolism of Lacosamide can be decreased when combined with Avapritinib.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Lacosamide is combined with Lemborexant.]
[L01XX72, tazemetostat, The metabolism of Tazemetostat can be decreased when combined with Lacosamide.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Lumateperone is combined with Lacosamide.]
[M01AX21, diacetylrhein, The metabolism of Lacosamide can be decreased when combined with Diacerein.]
[J05AB16, remdesivir, The metabolism of Lacosamide can be decreased when combined with Remdesivir.]
[H02CA02, osilodrostat, The metabolism of Lacosamide can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Lacosamide can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Frovatriptan is combined with Lacosamide.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Dichloralphenazone is combined with Lacosamide.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Lacosamide.]
[G03DB08, dienogest, The metabolism of Dienogest can be increased when combined with Lacosamide.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Difenoxin is combined with Lacosamide.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Lacosamide.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Lacosamide.]
[M01AH02, rofecoxib, The metabolism of Lacosamide can be increased when combined with Rofecoxib.]
[L01XF03, bexarotene, The metabolism of Lacosamide can be increased when combined with Bexarotene.]
[C08CA16, clevidipine, The metabolism of Lacosamide can be increased when combined with Clevidipine.]
[C01BD07, dronedarone, The metabolism of Dronedarone can be decreased when combined with Lacosamide.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Valpromide is combined with Lacosamide.]
[J01FA13, dirithromycin, The metabolism of Lacosamide can be decreased when combined with Dirithromycin.]
[L01AA02, chlorambucil, The therapeutic efficacy of Lacosamide can be decreased when used in combination with Chlorambucil.]
[S03AA08, chloramphenicol, The metabolism of Lacosamide can be decreased when combined with Chloramphenicol.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Lacosamide.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Lacosamide.]
[A03AA08, dihexyverine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[D07XB03, fluprednidene, The metabolism of Lacosamide can be increased when combined with Fluprednidene.]
[G04BD09, trospium, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Lacosamide is combined with Clomethiazole.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Chlormezanone is combined with Lacosamide.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Lacosamide is combined with Dyclonine.]
[R06AX22, ebastine, The metabolism of Ebastine can be decreased when combined with Lacosamide.]
[P01BB01, proguanil, The metabolism of Lacosamide can be decreased when combined with Proguanil.]
[N05CD14, remimazolam, The risk or severity of sedation can be increased when Lacosamide is combined with Remimazolam.]
[L04AC19, satralizumab, The serum concentration of Lacosamide can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Lacosamide is combined with Oliceridine.]
[P01BA01, chloroquine, The therapeutic efficacy of Lacosamide can be decreased when used in combination with Chloroquine.]
[L01EX23, pralsetinib, The metabolism of Lacosamide can be increased when combined with Pralsetinib.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Lacosamide.]
[N05AA01, chlorpromazine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.]
[A10BB02, chlorpropamide, The metabolism of Lacosamide can be decreased when combined with Chlorpropamide.]
[N05AF03, chlorprothixene, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Lacosamide.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Lacosamide is combined with Etifoxine.]
[N06BX18, vinpocetine, The risk or severity of adverse effects can be increased when Lacosamide is combined with Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Lacosamide.]
[G03DC06, ethynodiol, The metabolism of Etynodiol can be increased when combined with Lacosamide.]
[M01AB08, etodolac, The metabolism of Lacosamide can be decreased when combined with Etodolac.]
[B06AC06, berotralstat, The metabolism of Lacosamide can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Lacosamide can be decreased when combined with Lonafarnib.]
[P03AX07, abametapir, The serum concentration of Lacosamide can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The metabolism of Lacosamide can be decreased when combined with Tepotinib.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Lacosamide is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of adverse effects can be increased when Felbamate is combined with Lacosamide.]
[N06BA10, fenethylline, Lacosamide may increase the excretion rate of Fenethylline which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA03, flunisolide, The metabolism of Lacosamide can be increased when combined with Flunisolide.]
[S02BA08, fluocinolone acetonide, The metabolism of Lacosamide can be increased when combined with Fluocinolone acetonide.]
[R03CC15, formoterol, The metabolism of Lacosamide can be decreased when combined with Formoterol.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Lacosamide.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Lacosamide is combined with Trichloroethylene.]
[L03AB10, peginterferon alfa-2b, The metabolism of Lacosamide can be increased when combined with Peginterferon alfa-2b.]
[A02BA01, cimetidine, The metabolism of Lacosamide can be decreased when combined with Cimetidine.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Gabapentin is combined with Lacosamide.]
[N07CA02, cinnarizine, Cinnarizine may increase the bradycardic activities of Lacosamide.]
[L01XX73, sotorasib, The serum concentration of Lacosamide can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be decreased when combined with Lacosamide.]
[S03AA07, ciprofloxacin, The metabolism of Lacosamide can be decreased when combined with Ciprofloxacin.]
[N06AB04, citalopram, The risk or severity of adverse effects can be increased when Lacosamide is combined with Citalopram.]
[H01AC07, somapacitan, The metabolism of Lacosamide can be decreased when combined with Somapacitan.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Lacosamide is combined with Fexinidazole.]
[L01XX74, belzutifan, The metabolism of Belzutifan can be decreased when combined with Lacosamide.]
[L04AA59, avacopan, The metabolism of Lacosamide can be decreased when combined with Avacopan.]
[R06AA04, clemastine, The risk or severity of adverse effects can be increased when Clemastine is combined with Lacosamide.]
[A10BB12, glimepiride, The metabolism of Lacosamide can be decreased when combined with Glimepiride.]
[A10BB08, gliquidone, The metabolism of Lacosamide can be decreased when combined with Gliquidone.]
[N06AX25, St. John's wort extract, The metabolism of Lacosamide can be increased when combined with St. John's Wort.]
[L01EA06, asciminib, The metabolism of Lacosamide can be decreased when combined with Asciminib.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Lacosamide.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Lacosamide.]
[J04BA01, clofazimine, The metabolism of Lacosamide can be decreased when combined with Clofazimine.]
[C10AB01, clofibrate, The metabolism of Lacosamide can be increased when combined with Clofibrate.]
[B06AX04, mitapivat, The metabolism of Lacosamide can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Lacosamide is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The metabolism of Lacosamide can be decreased when combined with Pacritinib.]
[N06AA04, clomipramine, The metabolism of Lacosamide can be decreased when combined with Clomipramine.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Clonazepam is combined with Lacosamide.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Lacosamide.]
[C01EB24, mavacamten, The serum concentration of Lacosamide can be decreased when it is combined with Mavacamten.]
[A02BC08, vonoprazan, The metabolism of Lacosamide can be decreased when combined with Vonoprazan.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Lacosamide is combined with Clothiapine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Clotiazepam is combined with Lacosamide.]
[A04AA01, ondansetron, The risk or severity of adverse effects can be increased when Ondansetron is combined with Lacosamide.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Granisetron is combined with Lacosamide.]
[N05AH02, clozapine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Clozapine.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Halazepam is combined with Lacosamide.]
[H01AC08, somatrogon, The metabolism of Lacosamide can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Lacosamide is combined with Cocaine.]
[C02KB01, metyrosine, Lacosamide may increase the sedative activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Lacosamide can be increased when combined with Bimekizumab.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Codeine is combined with Lacosamide.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Hexafluronium is combined with Lacosamide.]
[A03AB10, hexocyclium, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[L04AA13, leflunomide, The metabolism of Lacosamide can be decreased when combined with Leflunomide.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Desflurane is combined with Lacosamide.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Lacosamide is combined with Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Lacosamide is combined with Ifenprodil.]
[A10BX03, nateglinide, The metabolism of Lacosamide can be decreased when combined with Nateglinide.]
[J01FA15, telithromycin, The metabolism of Lacosamide can be decreased when combined with Telithromycin.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Desloratadine is combined with Lacosamide.]
[J05AB14, valganciclovir, The therapeutic efficacy of Lacosamide can be decreased when used in combination with Valganciclovir.]
[M01AH03, valdecoxib, The metabolism of Lacosamide can be decreased when combined with Valdecoxib.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Almotriptan is combined with Lacosamide.]
[M01AH04, parecoxib, The metabolism of Parecoxib can be decreased when combined with Lacosamide.]
[J02AC02, itraconazole, The metabolism of Lacosamide can be decreased when combined with Itraconazole.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Ketazolam is combined with Lacosamide.]
[L01EA01, imatinib, The metabolism of Lacosamide can be decreased when combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Lacosamide can be decreased when combined with Posaconazole.]
[A02BC05, esomeprazole, The metabolism of Lacosamide can be decreased when combined with Esomeprazole.]
[C08CA09, lacidipine, Lacosamide may increase the bradycardic activities of Lacidipine.]
[N03AX09, lamotrigine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.]
[S01BA03, cortisone, The metabolism of Lacosamide can be increased when combined with Cortisone.]
[N07BC04, lofexidine, The therapeutic efficacy of Lacosamide can be increased when used in combination with Lofexidine.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Lacosamide is combined with Lormetazepam.]
[H01AA02, cosyntropin, The risk or severity of liver damage can be increased when Tetracosactide is combined with Lacosamide.]
[C08CA11, manidipine, The metabolism of Lacosamide can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Lacosamide is combined with Medifoxamine.]
[C07AA14, mepindolol, Lacosamide may increase the bradycardic activities of Mepindolol.]
[H02AB15, meprednisone, The metabolism of Lacosamide can be increased when combined with Meprednisone.]
[R06AD07, mequitazine, The metabolism of Lacosamide can be decreased when combined with Mequitazine.]
[R06AD04, methdilazine, The therapeutic efficacy of Lacosamide can be decreased when used in combination with Methdilazine.]
[N04AA03, methixene, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[C04AX01, cyclandelate, Cyclandelate may increase the bradycardic activities of Lacosamide.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Cyclizine is combined with Lacosamide.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Lacosamide is combined with Cyclobarbital.]
[N05AD03, metylperon, The risk or severity of adverse effects can be increased when Lacosamide is combined with Melperone.]
[J01FA03, midecamycin, The metabolism of Lacosamide can be decreased when combined with Midecamycin.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Lacosamide.]
[N06AX07, minaprine, The risk or severity of adverse effects can be increased when Minaprine is combined with Lacosamide.]
[S01XA18, cyclosporine, The metabolism of Cyclosporine can be decreased when combined with Lacosamide.]
[N06AG02, moclobemide, The risk or severity of adverse effects can be increased when Moclobemide is combined with Lacosamide.]
[N06BA07, modafinil, The metabolism of Lacosamide can be decreased when combined with Modafinil.]
[R06AX02, cyproheptadine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.]
[C10AA07, rosuvastatin, The metabolism of Lacosamide can be decreased when combined with Rosuvastatin.]
[C03XA02, conivaptan, The metabolism of Lacosamide can be decreased when combined with Conivaptan.]
[M01AH05, etoricoxib, The metabolism of Lacosamide can be decreased when combined with Etoricoxib.]
[G03XA01, danazol, The metabolism of Lacosamide can be decreased when combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Dantrolene is combined with Lacosamide.]
[J04BA02, dapsone, The metabolism of Lacosamide can be decreased when combined with Dapsone.]
[L01DB02, daunorubicin, The metabolism of Lacosamide can be decreased when combined with Daunorubicin.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Lacosamide is combined with Deanol.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Lacosamide.]
[M01AX01, nabumetone, The metabolism of Lacosamide can be decreased when combined with Nabumetone.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Lacosamide is combined with Nordazepam.]
[C07AB12, nebivolol, The metabolism of Lacosamide can be decreased when combined with Nebivolol.]
[N06AX06, nefazodone, The metabolism of Lacosamide can be decreased when combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Lacosamide is combined with Niaprazine.]
[L02BB02, nilutamide, The metabolism of Lacosamide can be decreased when combined with Nilutamide.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Tiagabine is combined with Lacosamide.]
[G03DB04, nomegestrol, The metabolism of Nomegestrol can be increased when combined with Lacosamide.]
[C01CA23, theodrenaline, Lacosamide may increase the excretion rate of Theodrenaline which could result in a lower serum level and potentially a reduction in efficacy.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Lacosamide.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Lacosamide is combined with Normethadone.]
[N06AB10, escitalopram, The risk or severity of adverse effects can be increased when Lacosamide is combined with Escitalopram.]
[G04BD08, solifenacin, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[N06AA01, desipramine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Desipramine.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Lacosamide.]
[S03BA01, dexamethasone, The metabolism of Lacosamide can be increased when combined with Dexamethasone.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Lacosamide is combined with Oxiracetam.]
[N04AA08, dexetimide, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A03AA01, oxyphencyclimine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Lacosamide can be increased when combined with Adalimumab.]
[N06BA02, dextroamphetamine, The therapeutic efficacy of Lacosamide can be decreased when used in combination with Amphetamine.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Lacosamide.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Paramethadione is combined with Lacosamide.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Dextromoramide is combined with Lacosamide.]
[N06AB05, paroxetine, The risk or severity of adverse effects can be increased when Lacosamide is combined with Paroxetine.]
[B01AC04, clopidogrel, The metabolism of Lacosamide can be decreased when combined with Clopidogrel.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Diamorphine is combined with Lacosamide.]
[C04AD01, pentifylline, Lacosamide may increase the excretion rate of Pentifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Diazepam is combined with Lacosamide.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Phenacemide is combined with Lacosamide.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Lacosamide is combined with Phenol.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Phensuximide is combined with Lacosamide.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Lacosamide is combined with Dibenzepin.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Lacosamide is combined with Cinchocaine.]
[S01BC03, diclofenac, The metabolism of Lacosamide can be decreased when combined with Diclofenac.]
[J01CF01, dicloxacillin, The metabolism of Lacosamide can be increased when combined with Dicloxacillin.]
[A03AA07, dicyclomine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[A03AX04, pinaverium, Lacosamide may increase the bradycardic activities of Pinaverium.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Lacosamide is combined with Pipamperone.]
[A03AB14, pipenzolate, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01DC04, ixabepilone, The metabolism of Ixabepilone can be decreased when combined with Lacosamide.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Lacosamide.]
[A08AA03, diethylpropion, The risk or severity of adverse effects can be increased when Diethylpropion is combined with Lacosamide.]
[L02AA01, diethylstilbestrol, The metabolism of Diethylstilbestrol can be increased when combined with Lacosamide.]
[C08CA03, isradipine, The metabolism of Lacosamide can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The metabolism of Lacosamide can be increased when combined with Difluocortolone.]
[A03AB11, poldine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[C01AA04, digitoxin, The metabolism of Digitoxin can be decreased when combined with Lacosamide.]
[C01AA05, digoxin, Digoxin may increase the bradycardic activities of Lacosamide.]
[C04AE04, dihydroergocristine, The metabolism of Dihydroergocristine can be decreased when combined with Lacosamide.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be decreased when combined with Lacosamide.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Lacosamide.]
[J05AE08, atazanavir, The metabolism of Lacosamide can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The metabolism of Lacosamide can be decreased when combined with Treprostinil.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Lacosamide is combined with Pramocaine.]
[C08DB01, diltiazem, The metabolism of Lacosamide can be decreased when combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Lacosamide.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Lacosamide is combined with Pridinol.]
[R06AB03, dimethindene, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[M02AX03, dimethyl sulfoxide, The metabolism of Lacosamide can be decreased when combined with Dimethyl sulfoxide.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Progabide is combined with Lacosamide.]
[N06BC02, propentofylline, Lacosamide may increase the excretion rate of Propentofylline which could result in a lower serum level and potentially a reduction in efficacy.]
[C05CA03, diosmin, The metabolism of Lacosamide can be decreased when combined with Diosmin.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Lacosamide is combined with Proparacaine.]
[R03DA03, proxyphylline, Lacosamide may increase the excretion rate of Proxyphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Lacosamide is combined with Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Lacosamide.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Quazepam is combined with Lacosamide.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Lacosamide is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Lacosamide is combined with Quinupramine.]
[A03FA02, cisapride, The risk or severity of adverse effects can be increased when Cisapride is combined with Lacosamide.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be decreased when combined with Lacosamide.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Remoxipride is combined with Lacosamide.]
[C01BA03, disopyramide, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[P03AA04, disulfiram, The therapeutic efficacy of Lacosamide can be decreased when used in combination with Disulfiram.]
[S02AA12, rifamycin SV, The metabolism of Lacosamide can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Lacosamide can be increased when combined with Rifapentine.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Riluzole is combined with Lacosamide.]
[N05AX08, risperidone, The risk or severity of adverse effects can be increased when Risperidone is combined with Lacosamide.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Lacosamide is combined with Levocetirizine.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Lacosamide is combined with Ropivacaine.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be decreased when combined with Lacosamide.]
[A04AD12, aprepitant, The metabolism of Lacosamide can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be decreased when combined with Lacosamide.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be decreased when combined with Lacosamide.]
[J05AE07, fosamprenavir, The metabolism of Lacosamide can be decreased when combined with Fosamprenavir.]
[S01BC05, ketorolac, The metabolism of Lacosamide can be decreased when combined with Ketorolac.]
[C01EB18, ranolazine, The metabolism of Lacosamide can be decreased when combined with Ranolazine.]
[N06AA16, dothiepin, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Dosulepin.]
[N06AA12, doxepin, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[L01DB01, doxorubicin, The metabolism of Doxorubicin can be decreased when combined with Lacosamide.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lacosamide.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Lacosamide is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Sevoflurane is combined with Lacosamide.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Lacosamide.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Lacosamide is combined with Sibutramine.]
[C10AA01, simvastatin, The metabolism of Lacosamide can be decreased when combined with Simvastatin.]
[V03AG05, sodium phosphate, The therapeutic efficacy of Lacosamide can be decreased when used in combination with Sodium phosphate, monobasic.]
[R03DA01, dyphylline, Lacosamide may increase the excretion rate of Dyphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Lacosamide is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Sumatriptan is combined with Lacosamide.]
[C07AB13, talinolol, Lacosamide may increase the bradycardic activities of Talinolol.]
[H01AA01, corticotropin, The metabolism of Lacosamide can be increased when combined with Corticotropin.]
[M01AC02, tenoxicam, The metabolism of Lacosamide can be decreased when combined with Tenoxicam.]
[D01BA02, terbinafine, The metabolism of Lacosamide can be increased when combined with Terbinafine.]
[G04BD05, terodiline, Lacosamide may increase the bradycardic activities of Terodiline.]
[C07AA16, tertatolol, Lacosamide may increase the bradycardic activities of Tertatolol.]
[A08AB01, orlistat, Orlistat can cause a decrease in the absorption of Lacosamide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Lacosamide is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Lacosamide is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Lacosamide is combined with Thiopropazate.]
[G04BD01, emepronium, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be decreased when combined with Lacosamide.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Lacosamide is combined with Tofisopam.]
[M01AG02, tolfenamic acid, Lacosamide may increase the bradycardic activities of Tolfenamic acid.]
[N06AG03, toloxatone, The risk or severity of adverse effects can be increased when Lacosamide is combined with Toloxatone.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Lacosamide.]
[C03CA04, torsemide, The metabolism of Lacosamide can be decreased when combined with Torasemide.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Lacosamide is combined with Loprazolam.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Lacosamide.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Lacosamide is combined with Triclofos.]
[A03AB08, tridihexethyl, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Lacosamide.]
[N04AA12, tropatepine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Lacosamide.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Lacosamide is combined with Urapidil.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Lacosamide is combined with Veralipride.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be decreased when combined with Lacosamide.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Epinastine is combined with Lacosamide.]
[N06AX16, venlafaxine, The risk or severity of adverse effects can be increased when Venlafaxine is combined with Lacosamide.]
[C08CA12, mepirodipine, The metabolism of Lacosamide can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The metabolism of Lacosamide can be decreased when combined with Epinephrine.]
[N05CF02, zolpidem, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[N03AX15, zonisamide, The risk or severity of adverse effects can be increased when Zonisamide is combined with Lacosamide.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Lacosamide is combined with Zopiclone.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Lacosamide is combined with Zotepine.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Lacosamide.]
[C01BG01, moricizine, The risk or severity of adverse effects can be increased when Moricizine is combined with Lacosamide.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Ergometrine is combined with Lacosamide.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Lacosamide.]
[N02CA02, ergotamine, The metabolism of Lacosamide can be decreased when combined with Ergotamine.]
[N03AG01, valproic acid, The risk or severity of adverse effects can be increased when Valproic acid is combined with Lacosamide.]
[S01AA17, erythromycin, The metabolism of Lacosamide can be decreased when combined with Erythromycin.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Estazolam is combined with Lacosamide.]
[A02BC02, pantoprazole, The metabolism of Lacosamide can be decreased when combined with Pantoprazole.]
[G03CA03, estradiol, The metabolism of Estradiol can be increased when combined with Lacosamide.]
[J04AK02, ethambutol, The metabolism of Lacosamide can be decreased when combined with Ethambutol.]
[R03BA05, fluticasone, The metabolism of Lacosamide can be increased when combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Lacosamide can be decreased when combined with Fluvastatin.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lacosamide.]
[L02AA03, ethinyl estradiol, The metabolism of Ethinylestradiol can be increased when combined with Lacosamide.]
[N04AA05, profenamine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, The risk or severity of adverse effects can be increased when Ethosuximide is combined with Lacosamide.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Ethotoin is combined with Lacosamide.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Lacosamide is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Lacosamide is combined with Meloxicam.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Lacosamide.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Lacosamide is combined with Etidocaine.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Lacosamide.]
[L01CB01, etoposide, The metabolism of Etoposide can be decreased when combined with Lacosamide.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Sertindole is combined with Lacosamide.]
[L04AD02, tacrolimus, The metabolism of Tacrolimus can be decreased when combined with Lacosamide.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Lacosamide.]
[R06AX12, terfenadine, The metabolism of Lacosamide can be decreased when combined with Terfenadine.]
[N06AX12, bupropion, The risk or severity of adverse effects can be increased when Bupropion is combined with Lacosamide.]
[N06AB08, fluvoxamine, The metabolism of Lacosamide can be decreased when combined with Fluvoxamine.]
[P02CA03, albendazole, The metabolism of Lacosamide can be decreased when combined with Albendazole.]
[C08CA02, felodipine, The metabolism of Lacosamide can be decreased when combined with Felodipine.]
[C08EA01, fendiline, Lacosamide may increase the bradycardic activities of Fendiline.]
[N03AX26, fenfluramine, The risk or severity of adverse effects can be increased when Fenfluramine is combined with Lacosamide.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Fentanyl is combined with Lacosamide.]
[G04BD02, flavoxate, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[C01BC04, flecainide, The metabolism of Lacosamide can be decreased when combined with Flecainide.]
[J01CF05, floxacillin, The metabolism of Lacosamide can be increased when combined with Flucloxacillin.]
[J02AC01, fluconazole, The metabolism of Lacosamide can be decreased when combined with Fluconazole.]
[N07CA03, flunarizine, The risk or severity of adverse effects can be increased when Flunarizine is combined with Lacosamide.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Lacosamide.]
[D07AC08, fluocinonide, The metabolism of Lacosamide can be increased when combined with Fluocinonide.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Lacosamide is combined with Melitracen.]
[H02AB03, fluocortolone, The metabolism of Lacosamide can be increased when combined with Fluocortolone.]
[V03AZ01, ethanol, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[L01BC09, floxuridine, The metabolism of Lacosamide can be decreased when combined with Floxuridine.]
[L01BC02, fluorouracil, The metabolism of Lacosamide can be decreased when combined with Fluorouracil.]
[N06AB03, fluoxetine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05AF01, flupenthixol, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Fluphenazine is combined with Lacosamide.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Flurazepam is combined with Lacosamide.]
[S01BC04, flurbiprofen, The metabolism of Lacosamide can be decreased when combined with Flurbiprofen.]
[N05AG01, fluspirilene, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Lacosamide.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Lacosamide is combined with Alcuronium.]
[G01AX06, furazolidone, The risk or severity of adverse effects can be increased when Furazolidone is combined with Lacosamide.]
[J05AE10, darunavir, The metabolism of Lacosamide can be decreased when combined with Darunavir.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Lacosamide is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of adverse effects can be increased when Lacosamide is combined with Amisulpride.]
[N06DA04, galantamine, Galantamine may increase the bradycardic activities of Lacosamide.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Lacosamide is combined with Gallamine.]
[C08DA02, gallopamil, Lacosamide may increase the bradycardic activities of Gallopamil.]
[S01AD09, ganciclovir, The therapeutic efficacy of Lacosamide can be decreased when used in combination with Ganciclovir.]
[N03AA04, barbexaclone, The risk or severity of adverse effects can be increased when Lacosamide is combined with Barbexaclone.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Lacosamide is combined with Bifemelane.]
[C10AB04, gemfibrozil, The metabolism of Lacosamide can be decreased when combined with Gemfibrozil.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be decreased when combined with Lacosamide.]
[N04BC06, cabergoline, The metabolism of Cabergoline can be decreased when combined with Lacosamide.]
[C01CA21, cafedrine, Lacosamide may increase the excretion rate of Cafedrine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AG04, etravirine, The metabolism of Lacosamide can be increased when combined with Etravirine.]
[N03AD03, methsuximide, The risk or severity of adverse effects can be increased when Methsuximide is combined with Lacosamide.]
[G03XA02, gestrinone, The metabolism of Gestrinone can be increased when combined with Lacosamide.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Alfentanil is combined with Lacosamide.]
[L01EH01, lapatinib, The metabolism of Lacosamide can be decreased when combined with Lapatinib.]
[A10BB01, glyburide, The metabolism of Lacosamide can be decreased when combined with Glyburide.]
[A10BB09, gliclazide, The metabolism of Lacosamide can be decreased when combined with Gliclazide.]
[A10BB07, glipizide, The metabolism of Lacosamide can be decreased when combined with Glipizide.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Lacosamide.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Glutethimide is combined with Lacosamide.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be decreased when combined with Lacosamide.]
[C02CA04, doxazosin, The metabolism of Lacosamide can be decreased when combined with Doxazosin.]
[L01EX02, sorafenib, The metabolism of Lacosamide can be decreased when combined with Sorafenib.]
[C07AB09, esmolol, Esmolol may increase the bradycardic activities of Lacosamide.]
[B01AA12, fluindione, The metabolism of Fluindione can be decreased when combined with Lacosamide.]
[D01BA01, griseofulvin, The metabolism of Lacosamide can be increased when combined with Griseofulvin.]
[P01BX01, halofantrine, The therapeutic efficacy of Lacosamide can be decreased when used in combination with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Lacosamide.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Halothane is combined with Lacosamide.]
[N05AH04, quetiapine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Lacosamide is combined with Iprazochrome.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be decreased when combined with Lacosamide.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Lacosamide is combined with Allobarbital.]
[C09CA01, losartan, The metabolism of Lacosamide can be decreased when combined with Losartan.]
[G03DC01, allylestrenol, The metabolism of Lacosamide can be decreased when combined with Allylestrenol.]
[N05CA16, hexobarbital, The risk or severity of adverse effects can be increased when Hexobarbital is combined with Lacosamide.]
[J05AG01, nevirapine, The metabolism of Lacosamide can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The metabolism of Lacosamide can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, Nimesulide may increase the bradycardic activities of Lacosamide.]
[C02DB02, hydralazine, The metabolism of Lacosamide can be decreased when combined with Hydralazine.]
[R05DA03, hydrocodone, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[S02BA01, hydrocortisone, The metabolism of Lacosamide can be increased when combined with Hydrocortisone.]
[D07AB02, hydrocortisone butyrate, The metabolism of Lacosamide can be increased when combined with Hydrocortisone butyrate.]
[G04BD06, propiverine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[P01BA02, hydroxychloroquine, The therapeutic efficacy of Lacosamide can be decreased when used in combination with Hydroxychloroquine.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Lacosamide is combined with Prothipendyl.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Lacosamide.]
[J04AB04, rifabutin, The metabolism of Lacosamide can be increased when combined with Rifabutin.]
[R02AX02, ibuprofen, The metabolism of Lacosamide can be decreased when combined with Ibuprofen.]
[L01DB06, idarubicin, The metabolism of Lacosamide can be decreased when combined with Idarubicin.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be decreased when combined with Lacosamide.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Sufentanil is combined with Lacosamide.]
[N06AA02, imipramine, The metabolism of Lacosamide can be decreased when combined with Imipramine.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Lacosamide.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Tizanidine is combined with Lacosamide.]
[L01CE01, topotecan, Lacosamide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC01, indomethacin, The metabolism of Lacosamide can be decreased when combined with Indomethacin.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Lacosamide is combined with Milnacipran.]
[A03AA30, piperidolate, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Lacosamide is combined with Articaine.]
[V08AB02, iohexol, The therapeutic efficacy of Lacosamide can be decreased when used in combination with Iohexol.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Alprazolam is combined with Lacosamide.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Ramelteon is combined with Lacosamide.]
[R06AE01, buclizine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[C10AA06, cerivastatin, The metabolism of Lacosamide can be increased when combined with Cerivastatin.]
[C07AA01, alprenolol, The risk or severity of adverse effects can be increased when Alprenolol is combined with Lacosamide.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Lacosamide is combined with Iprindole.]
[N06AF05, iproniazid, The risk or severity of adverse effects can be increased when Iproniazid is combined with Lacosamide.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Lacosamide is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Lacosamide.]
[P01AX06, atovaquone, The metabolism of Lacosamide can be decreased when combined with Atovaquone.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Lacosamide.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Entacapone is combined with Lacosamide.]
[J04AC01, isoniazid, The metabolism of Lacosamide can be decreased when combined with Isoniazid.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Lacosamide.]
[L04AC07, tocilizumab, The metabolism of Lacosamide can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Ketamine is combined with Lacosamide.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Lacosamide is combined with Ketanserin.]
[B01AC22, prasugrel, The metabolism of Lacosamide can be decreased when combined with Prasugrel.]
[J02AB02, ketoconazole, The metabolism of Lacosamide can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Lacosamide can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.]
[V03AC03, deferasirox, The metabolism of Lacosamide can be increased when combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Lacosamide can be increased when combined with Abatacept.]
[N04BC09, rotigotine, Lacosamide may increase the sedative activities of Rotigotine.]
[D11AX02, gamma-linolenic acid, The therapeutic efficacy of Lacosamide can be decreased when used in combination with Gamolenic acid.]
[C07AG01, labetalol, The metabolism of Lacosamide can be decreased when combined with Labetalol.]
[N07XX04, sodium oxybate, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[M01AG01, mefenamic acid, The metabolism of Lacosamide can be decreased when combined with Mefenamic acid.]
[R03BA09, fluticasone furoate, The metabolism of Lacosamide can be increased when combined with Fluticasone furoate.]
[J01MB02, nalidixic acid, The therapeutic efficacy of Lacosamide can be decreased when used in combination with Nalidixic acid.]
[G03AD01, levonorgestrel, The metabolism of Levonorgestrel can be increased when combined with Lacosamide.]
[N04BA01, levodopa, The risk or severity of adverse effects can be increased when Levodopa is combined with Lacosamide.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Lacosamide is combined with Lidocaine.]
[C08EX01, lidoflazine, Lacosamide may increase the bradycardic activities of Lidoflazine.]
[N06BA13, armodafinil, The metabolism of Lacosamide can be decreased when combined with Armodafinil.]
[N02CA07, lisuride, The risk or severity of adverse effects can be increased when Lisuride is combined with Lacosamide.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Lacosamide is combined with Lofepramine.]
[A07DA03, loperamide, Loperamide may increase the bradycardic activities of Lacosamide.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Lacosamide.]
[C10AA02, lovastatin, The metabolism of Lacosamide can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Loxapine is combined with Lacosamide.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be increased when combined with Lacosamide.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be decreased when combined with Lacosamide.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Lacosamide can be increased when used in combination with Magnesium sulfate.]
[L01EA03, nilotinib, The metabolism of Lacosamide can be decreased when combined with Nilotinib.]
[N06AA21, maprotiline, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Lacosamide.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Meclizine is combined with Lacosamide.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Lacosamide is combined with Medazepam.]
[P01BC02, mefloquine, The therapeutic efficacy of Lacosamide can be decreased when used in combination with Mefloquine.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Melatonin is combined with Lacosamide.]
[N06DX01, memantine, The metabolism of Lacosamide can be decreased when combined with Memantine.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Meperidine is combined with Lacosamide.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Mephenytoin is combined with Lacosamide.]
[N03AA01, mephobarbital, The metabolism of Lacosamide can be increased when combined with Methylphenobarbital.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Lacosamide is combined with Mepivacaine.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Lacosamide.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Lacosamide is combined with Meptazinol.]
[L02BG01, aminoglutethimide, The metabolism of Lacosamide can be increased when combined with Aminoglutethimide.]
[N05AC03, mesoridazine, The risk or severity of adverse effects can be increased when Mesoridazine is combined with Lacosamide.]
[N05AX13, paliperidone, The risk or severity of adverse effects can be increased when Paliperidone is combined with Lacosamide.]
[A04AA04, dolasetron, The risk or severity of adverse effects can be increased when Dolasetron is combined with Lacosamide.]
[H01CB03, lanreotide, Lacosamide may increase the bradycardic activities of Lanreotide.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Lacosamide.]
[N06BA03, methamphetamine, The risk or severity of adverse effects can be increased when Metamfetamine is combined with Lacosamide.]
[A03AB07, methantheline, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Methapyrilene is combined with Lacosamide.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Methaqualone is combined with Lacosamide.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Lacosamide.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Lacosamide is combined with Metergoline.]
[H03BB02, methimazole, The metabolism of Lacosamide can be decreased when combined with Methimazole.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Lacosamide.]
[N05CA15, methohexital, The risk or severity of adverse effects can be increased when Methohexital is combined with Lacosamide.]
[N02BG08, ziconotide, The risk or severity of CNS depression can be increased when Lacosamide is combined with Ziconotide.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be decreased when combined with Lacosamide.]
[N05AA02, methotrimeprazine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Lacosamide.]
[C02AB01, methyldopa, Methyldopa may increase the bradycardic activities of Lacosamide.]
[V04CG05, methylene blue, The risk or severity of adverse effects can be increased when Lacosamide is combined with Methylene blue.]
[G02AB01, methylergonovine, The metabolism of Lacosamide can be decreased when combined with Methylergometrine.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Lacosamide.]
[N06BA04, methylphenidate, The therapeutic efficacy of Lacosamide can be decreased when used in combination with Methylphenidate.]
[H02AB04, methylprednisolone, The metabolism of Lacosamide can be increased when combined with Methylprednisolone.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Lacosamide.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Methyprylon is combined with Lacosamide.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methysergide is combined with Lacosamide.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Lacosamide.]
[C07AB02, metoprolol, Metoprolol may increase the bradycardic activities of Lacosamide.]
[P01AB01, metronidazole, The metabolism of Lacosamide can be decreased when combined with Metronidazole.]
[V04CD01, metyrapone, The metabolism of Lacosamide can be increased when combined with Metyrapone.]
[N06AX03, mianserin, The therapeutic efficacy of Lacosamide can be decreased when used in combination with Mianserin.]
[S02AA13, miconazole, The metabolism of Lacosamide can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Lacosamide can be decreased when combined with Aminophenazone.]
[N05CD08, midazolam, The risk or severity of adverse effects can be increased when Midazolam is combined with Lacosamide.]
[C01CA17, midodrine, Midodrine may increase the bradycardic activities of Lacosamide.]
[G03XB01, mifepristone, The metabolism of Mifepristone can be increased when combined with Lacosamide.]
[C09CA03, valsartan, The metabolism of Lacosamide can be decreased when combined with Valsartan.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Lacosamide.]
[J01FA11, miocamycin, The metabolism of Lacosamide can be decreased when combined with Miocamycin.]
[L01XX23, mitotane, The metabolism of Lacosamide can be increased when combined with Mitotane.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Molindone is combined with Lacosamide.]
[L03AC01, aldesleukin, The metabolism of Lacosamide can be decreased when combined with Aldesleukin.]
[C01BD01, amiodarone, The metabolism of Lacosamide can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Lacosamide.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Palonosetron is combined with Lacosamide.]
[L04AB05, certolizumab pegol, The metabolism of Lacosamide can be increased when combined with Certolizumab pegol.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Lacosamide.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Vecuronium is combined with Lacosamide.]
[N05CA02, amobarbital, The risk or severity of adverse effects can be increased when Amobarbital is combined with Lacosamide.]
[P01BA06, amodiaquine, The metabolism of Lacosamide can be decreased when combined with Amodiaquine.]
[G03XC01, raloxifene, The metabolism of Lacosamide can be decreased when combined with Raloxifene.]
[N06AA17, amoxapine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.]
[N03AB05, fosphenytoin, The serum concentration of Lacosamide can be decreased when it is combined with Fosphenytoin.]
[C07AA12, nadolol, Nadolol may increase the bradycardic activities of Lacosamide.]
[N04BC04, ropinirole, Lacosamide may increase the sedative activities of Ropinirole.]
[J01CF06, nafcillin, The metabolism of Lacosamide can be increased when combined with Nafcillin.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Lacosamide is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Nalbuphine is combined with Lacosamide.]
[V03AB15, naloxone, The metabolism of Lacosamide can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The metabolism of Lacosamide can be increased when combined with Anakinra.]
[N06BA01, amphetamine, The therapeutic efficacy of Lacosamide can be decreased when used in combination with Amphetamine.]
[M02AA12, naproxen, The metabolism of Lacosamide can be decreased when combined with Naproxen.]
[A10BG01, troglitazone, The metabolism of Lacosamide can be decreased when combined with Troglitazone.]
[N06AX21, duloxetine, The risk or severity of adverse effects can be increased when Lacosamide is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Lacosamide.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be decreased when combined with Lacosamide.]
[L02BG04, letrozole, The metabolism of Lacosamide can be decreased when combined with Letrozole.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Remifentanil is combined with Lacosamide.]
[N05AX14, iloperidone, The risk or severity of adverse effects can be increased when Iloperidone is combined with Lacosamide.]
[J02AA01, amphotericin B, The therapeutic efficacy of Lacosamide can be decreased when used in combination with Amphotericin B.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Lacosamide is combined with Desvenlafaxine.]
[C09CA07, telmisartan, The metabolism of Lacosamide can be decreased when combined with Telmisartan.]
[C10AD02, niacin, The metabolism of Lacosamide can be decreased when combined with Niacin.]
[N06AF02, nialamide, The risk or severity of adverse effects can be increased when Nialamide is combined with Lacosamide.]
[C08CA04, nicardipine, The metabolism of Lacosamide can be decreased when combined with Nicardipine.]
[P02DA01, niclosamide, The metabolism of Niclosamide can be decreased when combined with Lacosamide.]
[C08CA05, nifedipine, Nifedipine may increase the bradycardic activities of Lacosamide.]
[C08CA06, nimodipine, Nimodipine may increase the bradycardic activities of Lacosamide.]
[C08CA07, nisoldipine, Nisoldipine may increase the bradycardic activities of Lacosamide.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Nitrazepam is combined with Lacosamide.]
[C08CA08, nitrendipine, Nitrendipine may increase the bradycardic activities of Lacosamide.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Zaleplon is combined with Lacosamide.]
[N04BC05, pramipexole, Lacosamide may increase the sedative activities of Pramipexole.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Lacosamide is combined with Nitrous oxide.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Nomifensine is combined with Lacosamide.]
[G03DC02, norethindrone, The metabolism of Norethisterone can be increased when combined with Lacosamide.]
[G03AC07, norgestrienone, The metabolism of Norgestrienone can be increased when combined with Lacosamide.]
[C02KX01, bosentan, The metabolism of Lacosamide can be increased when combined with Bosentan.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Lacosamide.]
[R05DA07, noscapine, The metabolism of Lacosamide can be decreased when combined with Noscapine.]
[G02CA02, nylidrin, Nylidrin may increase the bradycardic activities of Lacosamide.]
[H01CB02, octreotide, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Lacosamide.]
[J01FA05, oleandomycin, The metabolism of Lacosamide can be decreased when combined with Oleandomycin.]
[L04AC04, rilonacept, The metabolism of Lacosamide can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Lacosamide can be increased when combined with Omeprazole.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Lacosamide is combined with Opipramol.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Lacosamide is combined with Opium.]
[A14AA08, oxandrolone, The metabolism of Lacosamide can be decreased when combined with Oxandrolone.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Oxazepam is combined with Lacosamide.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Lacosamide.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Oxycodone is combined with Lacosamide.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Oxymorphone is combined with Lacosamide.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Lacosamide is combined with Oxypertine.]
[A03AB03, oxyphenonium, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[N05AH05, asenapine, The risk or severity of adverse effects can be increased when Asenapine is combined with Lacosamide.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Lacosamide.]
[M03AC01, pancuronium, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[G03DB06, chlormadinone, The metabolism of Chlormadinone can be increased when combined with Lacosamide.]
[N05CC05, paraldehyde, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[H02AB05, paramethasone, The metabolism of Lacosamide can be increased when combined with Paramethasone.]
[C02KC01, pargyline, The risk or severity of adverse effects can be increased when Pargyline is combined with Lacosamide.]
[G04BD11, fesoterodine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Penbutolol is combined with Lacosamide.]
[N05AG03, penfluridol, The risk or severity of adverse effects can be increased when Lacosamide is combined with Penfluridol.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Pentazocine is combined with Lacosamide.]
[N05CA01, pentobarbital, The metabolism of Lacosamide can be increased when combined with Pentobarbital.]
[C04AD03, pentoxifylline, Lacosamide may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Lacosamide is combined with Perazine.]
[N04BC02, pergolide, The risk or severity of adverse effects can be increased when Pergolide is combined with Lacosamide.]
[C08EX02, perhexiline, Perhexiline may increase the bradycardic activities of Lacosamide.]
[N05AB03, perphenazine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Lacosamide.]
[N02BE03, phenacetin, The metabolism of Lacosamide can be decreased when combined with Phenacetin.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Lacosamide is combined with Phenazocine.]
[N06AF03, phenelzine, The risk or severity of adverse effects can be increased when Phenelzine is combined with Lacosamide.]
[N03AA02, phenobarbital, The metabolism of Lacosamide can be increased when combined with Phenobarbital.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Lacosamide is combined with Phenoperidine.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Lacosamide.]
[M02AA01, phenylbutazone, The metabolism of Lacosamide can be increased when combined with Phenylbutazone.]
[A02BC06, dexlansoprazole, The metabolism of Lacosamide can be decreased when combined with Dexlansoprazole.]
[R01BA01, phenylpropanolamine, The therapeutic efficacy of Lacosamide can be decreased when used in combination with Phenylpropanolamine.]
[N03AB02, phenytoin, The serum concentration of Lacosamide can be decreased when it is combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Lacosamide can be increased when combined with Golimumab.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be decreased when combined with Lacosamide.]
[C08CX01, mibefradil, The metabolism of Lacosamide can be decreased when combined with Mibefradil.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Lacosamide.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Pindolol is combined with Lacosamide.]
[J05AE01, saquinavir, The metabolism of Lacosamide can be decreased when combined with Saquinavir.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Pipotiazine is combined with Lacosamide.]
[A02BX03, pirenzepine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Lacosamide is combined with Piritramide.]
[S01BC06, piroxicam, The metabolism of Lacosamide can be decreased when combined with Piroxicam.]
[N02CX01, pizotyline, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.]
[J05AG02, delavirdine, The serum concentration of Lacosamide can be increased when it is combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Lacosamide can be decreased when combined with Irbesartan.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Lacosamide is combined with Proxibarbal.]
[A10BG02, rosiglitazone, The metabolism of Lacosamide can be decreased when combined with Rosiglitazone.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Alosetron is combined with Lacosamide.]
[L04AC08, canakinumab, The metabolism of Lacosamide can be increased when combined with Canakinumab.]
[J05AE03, ritonavir, The serum concentration of Lacosamide can be increased when it is combined with Ritonavir.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be decreased when combined with Lacosamide.]
[C07AB01, practolol, Practolol may increase the bradycardic activities of Lacosamide.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Prazepam is combined with Lacosamide.]
[P02BA01, praziquantel, The metabolism of Lacosamide can be decreased when combined with Praziquantel.]
[S03BA02, prednisolone, The metabolism of Lacosamide can be increased when combined with Prednisolone.]
[C01DX02, prenylamine, Prenylamine may increase the bradycardic activities of Lacosamide.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Lacosamide is combined with Prilocaine.]
[P01BA03, primaquine, The metabolism of Lacosamide can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Lacosamide can be increased when combined with Primidone.]
[M04AB01, probenecid, The metabolism of Lacosamide can be increased when combined with Probenecid.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Lacosamide is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Lacosamide.]
[C10AB05, fenofibrate, The metabolism of Lacosamide can be decreased when combined with Fenofibrate.]
[N05AB04, prochlorperazine, The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lacosamide.]
[N04AA04, procyclidine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[G03DA04, progesterone, The metabolism of Progesterone can be increased when combined with Lacosamide.]
[N05AA03, promazine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Promazine.]
[R06AD02, promethazine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[C01BC03, propafenone, Propafenone may increase the bradycardic activities of Lacosamide.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Lacosamide is combined with Propanidid.]
[A03AB05, propantheline, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, The risk or severity of adverse effects can be increased when Periciazine is combined with Lacosamide.]
[N05CM06, propiomazine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be decreased when combined with Lacosamide.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Propofol is combined with Lacosamide.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Lacosamide.]
[C07AA05, propranolol, The metabolism of Lacosamide can be decreased when combined with Propranolol.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Rizatriptan is combined with Lacosamide.]
[R03DC03, montelukast, The metabolism of Lacosamide can be decreased when combined with Montelukast.]
[N06AA11, protriptyline, The risk or severity of adverse effects can be increased when Protriptyline is combined with Lacosamide.]
[N05AX12, aripiprazole, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.]
[A03AB15, diphemanil, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Lacosamide.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Lacosamide is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Lacosamide is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Lacosamide is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Lacosamide is combined with Pyrantel.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Lacosamide is combined with Mepyramine.]
[C01BA01, quinidine, The metabolism of Quinidine can be decreased when combined with Lacosamide.]
[P01BC01, quinine, The risk or severity of adverse effects can be increased when Quinine is combined with Lacosamide.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Lacosamide.]
[J04AB02, rifampin, The metabolism of Lacosamide can be increased when combined with Rifampicin.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Oxitriptan is combined with Lacosamide.]
[J01FA06, roxithromycin, The metabolism of Lacosamide can be decreased when combined with Roxithromycin.]
[S01BC08, salicylic acid, The metabolism of Lacosamide can be decreased when combined with Salicylic acid.]
[S01FA02, scopolamine, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, The risk or severity of adverse effects can be increased when Secobarbital is combined with Lacosamide.]
[N04BD01, selegiline, The risk or severity of adverse effects can be increased when Selegiline is combined with Lacosamide.]
[H01CB01, somatostatin, The metabolism of Lacosamide can be decreased when combined with Somatostatin.]
[C07AA07, sotalol, Sotalol may increase the bradycardic activities of Lacosamide.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Lacosamide.]
[R03BB01, ipratropium bromide, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
